Literature DB >> 32093437

Quality of life in inflammatory bowel diseases: it is not all about the bowel.

Ronald Keller1, Nazar Mazurak2, Laura Fantasia1, Stefano Fusco1, Nisar P Malek1, Jan Wehkamp1, Paul Enck2, Thomas Klag1.   

Abstract

BACKGROUND/AIMS: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life, and the quality of life (QUOL) interacts with disease activity, improving QUOL should be one of the main goals of therapy. This study aims to identify factors contributing to good or impaired QUOL.
METHODS: Questionnaires addressing health-related QUOL and other psychological and social features were positioned on our institutions' webpage and on the webpage of the largest self-help group for IBD in Germany. Patients were subdivided according to their QUOL score with a cutoff of <60. We used the Short Inflammatory Bowel Disease Questionnaire, the Assessment of the Demand for Additional Psychological Treatment, and the Fear of Progression Questionnaire Short Form.
RESULTS: High numbers of patients in both subgroups showed an impaired QUOL (87.34% in UC, 91.08% in CD). Active extraintestinal manifestations, smoking, high fear of progression and high demand for psychotherapy were associated with reduced QUOL. In addition, polypharmacological interventions did not result in a good QUOL, but ostomies are linked to improved QUOL especially in CD patients.
CONCLUSIONS: Scores used in clinical day-to-day-practice mainly focusing on somatic factors do not sufficiently address important aspects concerning QUOL. Most importantly, extraintestinal manifestations show a hitherto underestimated impact on QUOL.

Entities:  

Keywords:  Colitis, ulcerative; Crohn disease; Extraintestinal manifestations; Quality of life

Year:  2020        PMID: 32093437     DOI: 10.5217/ir.2019.00135

Source DB:  PubMed          Journal:  Intest Res        ISSN: 1598-9100


  4 in total

1.  Psychological Effects and Medication Adherence among Korean Patients with Inflammatory Bowel Disease during the Coronavirus Disease 2019 Pandemic: A Single-Center Survey.

Authors:  Ji Eun Ryu; Sung-Goo Kang; Sung Hoon Jung; Shin Hee Lee; Sang-Bum Kang
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

2.  Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease.

Authors:  Jose María Huguet; Xavier Cortés; Marta Maia Bosca-Watts; Marian Aguas; Nuria Maroto; Lidia Martí; Cirilo Amorós; Jose María Paredes
Journal:  World J Clin Cases       Date:  2021-12-26       Impact factor: 1.337

3.  Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis.

Authors:  Nagesh Kamat; Sudheer K Vuyyuru; Saurabh Kedia; Pabitra Sahu; Bhaskar Kante; Peeyush Kumar; Mukesh Kumar Ranjan; Mukesh Kumar Singh; Sambuddha Kumar; Vikas Sachdev; Govind Makharia; Vineet Ahuja
Journal:  Intest Res       Date:  2022-02-08

4.  The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study.

Authors:  Tiziana Larussa; Danilo Flauti; Ludovico Abenavoli; Luigi Boccuto; Evelina Suraci; Raffaella Marasco; Maria Imeneo; Francesco Luzza
Journal:  J Clin Med       Date:  2020-07-28       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.